A Phase IV Double-Blind Placebo-Controlled Multi-Center Trial To Study The Effects Of Evolocumab In Stage IV-V Chronic Kidney Disease: The Cardiovascular and Lipid-Lowering Effects Of Evolocumab In Advanced Chronic Kidney Disease Trial (EVO-CKD)
Brief description of study
The purpose of this study is to evaluate the effect of evolocumab (Repatha®)—a Food and Drug Administration (FDA)-approved biological drug that has been shown to reduce LDL cholesterol (bad cholesterol) Early data show that the beneftis of evolocumab may be increased as kidney function declines. This trial is therefore designed to provide additional evidence regarding the safety and cholesterol-lowering effects of evolocumab compared with placebo, a pill that has no therapeutic effect, in advanced CKD patients.
Clinical Study Identifier: s20-00405
ClinicalTrials.gov Identifier: NCT04510844
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
